These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2566628)

  • 1. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid.
    Straw GM; Bigelow LB; Kirch DG
    J Clin Psychopharmacol; 1989 Apr; 9(2):130-2. PubMed ID: 2566628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dosage haloperidol in chronic schizophrenia.
    McCreadie RG; MacDonald IM
    Br J Psychiatry; 1977 Sep; 131():310-6. PubMed ID: 334315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1990 Aug; 47(8):754-8. PubMed ID: 2378546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication.
    Giannini AJ; Loiselle RH; DiMarzio LR; Giannini MC
    Am J Psychiatry; 1987 Sep; 144(9):1207-9. PubMed ID: 3631319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
    Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
    Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol plasma levels and acute clinical change in schizophrenia.
    Coryell W; Kelly M; Perry PJ; Miller DD
    J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
    Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK
    Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.